What Aprecia Pharmaceuticals does

Aprecia Pharmaceuticals, LLC is a privately held specialty pharmaceutical company headquartered in Mason, Ohio, that commercializes binder jetting three-dimensional printing (3DP) for pharmaceutical manufacturing. Founded in 2003, the company operates under an exclusive worldwide license from MIT for pharmaceutical applications of 3DP technology, with the core approach tracing to doctoral research at MIT by current CTO Jaedeok Yoo. Aprecia's technology stack comprises three proprietary platforms: the ZipDose formulation platform (rapidly disintegrating oral dosage forms carrying up to 1,000 mg active ingredient per dose without compression), the Open Bed 3DP-Tablet Forming Platform (racetrack-based commercial-scale production without molds/dies), and the Z-Form Flex In Blister system (layer-by-layer printing directly into primary packaging with integrated Process Analytical Technology, in-line inspection, and full traceability). The company holds 126 granted patents and 52 pending patents covering the underlying machinery and pharmaceutical applications.

The company monetizes across three streams: licensing the 3DP technology platforms to pharmaceutical partners; providing specialty contract development and manufacturing organization (CDMO) services spanning pre-formulation, clinical trial supply, and commercial-scale cGMP production; and selling its proprietary FDA-approved product SPRITAM (levetiracetam)—the world's first 3D-printed prescription drug—through licensed distribution partner Prasco Laboratories, a related entity under controlling parent Scion Companies. SPRITAM is approved as adjunctive therapy for partial onset, myoclonic, and generalized tonic-clonic seizures, with a July 2025 label extension to nasogastric and gastrostomy tube administration.

Aprecia serves three customer segments: pharmaceutical and biotech companies seeking differentiated drug delivery formats and advanced manufacturing; patients with dysphagia and high-dose requirements (epilepsy, pediatric, geriatric, and tube-fed populations); and government/defense customers (U.S. HHS/ASPR and DARPA via the Battelle partnership for agile point-of-need manufacturing). The company maintains U.S. operations across Mason (HQ), Blue Ash (190,000 sq ft manufacturing), and a historical East Windsor, NJ facility, with international reach through partnerships with CMIC (Japan), Glatt (Europe), Nanoform (Finland), and Merck KGaA (functional excipients). Complementary strategic partnerships include Ohio State University, Purdue University/US Pharmacopeia, Apprentice.io (AI-powered MES), and STAQ Pharma.

Name

Aprecia Pharmaceuticals

Legal name

Aprecia Pharmaceuticals, LLC

Website

https://aprecia.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Aprecia Pharmaceuticals (Mason, OH) commercializes proprietary binder jetting 3D printing technology for pharmaceutical manufacturing under an exclusive MIT license. The company offers technology licensing, specialty CDMO development and manufacturing services, and SPRITAM (levetiracetam), the first FDA-approved 3D-printed drug.

Ownership category

akta.pro rank

Product category

Pharmaceutical 3D Printing / Specialty CDMO

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• 3D printed pharmaceuticals
• Pharmaceutical CDMO services
• Orodispersible tablet technology
• Novel drug formulation
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Langhorne

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Technology Licensing: Aprecia licenses its exclusive 3DP technology platform to pharmaceutical partners as a means to extend product lines, improve patient reach and experience, and address FDA requirements as a pediatric delivery form.
2. Contract Development and Manufacturing (CDMO Services): Aprecia operates as a specialty CDMO offering development services (novel formulations, 3DP manufacturing, reducing risk, and accelerating product development) and manufacturing services (from clinical trial supply to commercial-scale production) to pharmaceutical clients globally.
3. Proprietary Product Sales (SPRITAM): Aprecia's proprietary FDA-approved product SPRITAM (levetiracetam) is distributed by Prasco Laboratories. Revenue is generated through product sales via this licensing arrangement.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Aprecia Pharmaceuticals develops and manufactures pharmaceutical products using proprietary binder jet 3D printing (3DP) technology. The company operates as a specialty CDMO offering formulation development, cGMP manufacturing, and technology licensing to pharmaceutical partners, and commercializes the FDA-approved product SPRITAM (levetiracetam) — the world's first 3D-printed prescription drug. Core platforms include ZipDose Technology, Open Bed 3DP-Tablet Forming, and the Z-Form Flex In Blister 3DP-Tablet Production System.

Product overview

Aprecia Pharmaceuticals is a specialty pharmaceutical company offering a platform-plus-modules architecture centered on its proprietary ZipDose 3D printing technology. The core technology includes the Open Bed 3DP-Tablet Forming Platform for commercial-scale production and the Z-Form Flex In Blister system for primary packaging integration. The company's flagship commercial product is SPRITAM (levetiracetam), the world's first and only FDA-approved 3D printed pharmaceutical. Services include drug development, manufacturing, and CMC support. Aprecia holds 126 granted patents and 52 pending in 3DP pharmaceutical applications.

Differentiator

Problem solved

Functional benefit

Brands

• SPRITAM: The world's first and only FDA-approved 3D printed pharmaceutical product. SPRITAM (levetiracetam) is an oral suspension tablet for epilepsy treatment that rapidly disintegrates with a sip of liquid. Licensed to Prasco Laboratories.
• ZipDose
• ZipDose Technology
• ZipDose Technology Platform
• Z-Form Flex
• Open Bed 3DP-Tablet Forming Platform
• In Blister 3DP-Tablet Production System

Products and services

• SPRITAM (levetiracetam) The world's first and only FDA-approved 3D-printed pharmaceutical product. SPRITAM is a porous oral dosage form that rapidly disintegrates with a sip of liquid, enabling delivery of up to 1,000 mg of levetiracetam. Indicated as adjunctive therapy for epilepsy (partial onset, myoclonic, and primary generalized tonic-clonic seizures) in patients with swallowing difficulties; also approved for nasogastric (NG) and gastrostomy (G) tube administration. Distributed via Prasco Laboratories.
• ZipDose Technology Platform Proprietary 3D printing-based formulation platform that enables medicine to swiftly disperse in the patient's mouth with a sip of water or other liquid. Achieves dosage strengths commercially unattainable with current fast-melt technologies and supports engineered and coated particles (taste masking, modified release) on large-dose products because no compression is used during manufacturing.
• Open Bed 3DP-Tablet Forming Platform Production platform enabling 3DP-tablet printing without molds or dyes. Features a cam-driven oval racetrack with linked moving build trays, continuous powder feeding and spreading, stationary high-resolution printheads, unprinted powder capture and recirculation, and a humidity-controlled drying oven. Capable of producing orodispersible dosage forms in excess of 1,000 mg of active ingredients, with bed-to-bed powder transfer for rapid prototyping in early formulation.
• Z-Form Flex (In Blister 3DP-Tablet Production System) In-blister 3DP-tablet production system that prints tablets directly into primary packaging (in-cavity). Provides layer-by-layer precision control, ability to combine multiple APIs, integrated Process Analytical Technology (PAT), in-line inspection, surface logo printing, traceability at card and cavity level, and high-potent capabilities. Enables real-time release and full product traceability from bulk powder to packaged finished doses.
• Development Services Collaborative CDMO development services covering novel formulations, 3DP manufacturing feasibility, risk reduction, and accelerated product development. Includes pre-formulation studies, formulation development, analytical development, process development, and scale-up across orodispersible, sublingual/buccal, and traditional tablet formats.
• Manufacturing Services cGMP-compliant pharmaceutical manufacturing services from clinical trial supply (Phase I–III) through commercial-scale production. Performed in an FDA-inspected and registered facility. Leverages Aprecia's 3DP platforms with integrated PAT and real-time release capability.
• CMC Support Comprehensive Chemistry, Manufacturing, and Controls support including raw materials selection, analytical methods development, stability testing, physicochemical properties analysis, manufacturing best practices, and quality control for partners developing 3DP-enabled drug products.

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core, secondary and minor.

• Apprentice.iocoreTechnology or Integration · 16 September 2025Aprecia partnered with Apprentice.io to implement its AI-powered manufacturing platform at Aprecia's Ohio facility. The cloud-native platform delivers digital manufacturing capabilities and no-code integration tools to accelerate production workflows, ensure consistent execution at scale, and enable rapid deployment across multiple production sites.
• BattellecoreStrategic or Co-development Partner · 19 August 2025Battelle and Aprecia were awarded a DARPA agreement (through HHS/ASPR IBMSC funding) for the EQUIP-A-Pharma research program. Battelle is building a custom small-scale chemical synthesis platform while Aprecia provides its Z-Form Flex 3DP technology. The program aims to create agile pharmaceutical manufacturing sites producing both active pharmaceutical ingredients and finished dosage forms at the same location.
• Purdue UniversitysecondaryStrategic or Co-development Partner · 4 August 2021Purdue University, in partnership with US Pharmacopeia and sponsorship from Aprecia, launched a pharmaceutical 3D printing educational forum. Aprecia sponsors the series as the global leader in 3DP pharmaceutical manufacturing. The forum brings together global 3DP experts to discuss technological advancements in process, equipment, systems, product applications, and manufacturing capabilities.
• NanoformsecondaryStrategic or Co-development Partner · 21 April 2021Collaboration to explore synergies between Nanoform's nanoparticle technologies and Aprecia's ZipDose 3DP platform for nanoparticle-enabled 3DP dosage forms. Initial target: combining Nanoform's fast dissolution nanoformed particles with ZipDose for rapid disintegration to enable high-performance buccal and oral delivery. Benefits may include lower dosage products, less excipient content, and reduced pill burden.
• Glatt Pharmaceutical ServicessecondaryStrategic or Co-development Partner · 23 February 2021Glatt Pharmaceutical Services and Aprecia partnered to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's 3DP manufacturing. The collaboration targets existing products for modified release 505(b)(2) brand line extensions and new chemical entities through accelerated clinical development and patient-focused dosage forms.
• Battelle (Long-Term Partnership)coreStrategic or Co-development Partner · 21 December 2020Aprecia established a long-term partnership with Battelle to accelerate and expand pharmaceutical 3DP capabilities. Battelle provides development engineering support for equipment design and prototyping.
• CMICsecondaryChannel Partner/ Reseller/ Distributor · 7 March 2019Aprecia and CMIC, a leading CDMO in Japan, established an agreement to bring 3DP pharmaceutical products to Japan. CMIC provides business development and commercialization support in Japan.
• Ohio State UniversityminorStrategic or Co-development PartnerFostering educational leadership, talent development, and R&D support to drive innovation in pharmaceutical 3DP.
• Merck (Merck KGaA)secondaryTechnology or IntegrationMerck provides access to functional excipients for use with Aprecia's 3DP technology platforms. A scientific poster was published demonstrating binder jetting technology for tablet manufacturing of loaded Parteck SLC (a mesoporous silica product from Merck KGaA) for solubility enhancement.
• STAQ PharmaminorChannel Partner/ Reseller/ DistributorSTAQ Pharma provides critical medications for pediatric and adult patients across the United States. Nature of collaboration with Aprecia relates to ensuring reliable supply of essential medications.
• Massachusetts Institute of Technology (MIT)coreTechnology or IntegrationAprecia holds an exclusive, worldwide license from MIT for pharmaceutical applications of the 3DP technology. MIT's technology underlies Aprecia's ZipDose and 3DP manufacturing platforms.
• Prasco Laboratories / Scion CompaniescoreChannel Partner/ Reseller/ DistributorPrasco Laboratories, under Scion Companies (the controlling parent), holds a controlling interest in Aprecia and serves as the licensed distribution partner for SPRITAM (levetiracetam). SPRITAM is distributed by Prasco Laboratories.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Regional players

• CMIC Holdings: Leading Japanese CDMO and Aprecia's exclusive distribution/CDMO partner for 3DP pharmaceutical products in Japan. Direct regional channel partner and a comparable CDMO-type competitor inside the Japanese market.

Broad incumbents

• Cambrex (Permira portfolio): Specialty CDMO focused on small-molecule active pharmaceutical ingredients and finished dosage forms. Comparable in size and CDMO-style service offering, competing for similar pharma development and manufacturing programs.
• Alcami: US-headquartered specialty CDMO providing drug product development, manufacturing, and analytical services from clinical to commercial scale. Similar specialty-CDMO positioning to Aprecia's services business, but without a 3DP-native platform.
• Thermo Fisher Scientific (Patheon CDMO): Operates one of the largest global pharmaceutical CDMO networks via its Patheon business. Overlaps with Aprecia in clinical-through-commercial drug product services and has the scale to add 3D printing capabilities.
• Catalent: One of the world's largest pharmaceutical CDMOs across oral, injectable, and biologic dosage forms. Competes with Aprecia in pharma development and manufacturing services from clinical through commercial scale, but with a vastly broader portfolio.
• Lonza: Global CDMO with deep capabilities in small molecules, biologics, and cell & gene therapies. A broad incumbent competing for outsourced pharma development and manufacturing budgets that Aprecia also targets through its CDMO services.

Others

• Apprentice.io: Provider of an AI-powered, cloud-native manufacturing execution platform that Aprecia is deploying at its Ohio facility. Comparable as a manufacturing-software partner in Aprecia's 'Pharma 4.0' stack rather than as a direct CDMO competitor.
• Merck KGaA (Life Science / MilliporeSigma): Supplies functional excipients (e.g., Parteck SLC) used with Aprecia's 3DP binder jetting platforms. Indirectly comparable as a critical input supplier and strategic ecosystem partner for pharmaceutical 3DP applications.

Direct peers

• FabRx Ltd: UK-based pharmaceutical 3D printing company developing personalized medicines and printed dosage forms, including orodispersible tablets. Closest European direct competitor in pharma-grade 3DP.
• TRIASTEK: Chinese-founded 3D-printed pharmaceutical company also cited as a leading global player alongside Aprecia in the 3D printed drugs market. Most direct head-to-head on binder-jetting oral dosage form technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/Aprecia3DP
• LinkedInlinkedin.com/company/aprecia-pharmaceuticals

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aprecia Pharmaceuticals